Pharmacokinetics of pirprofen and its pyrrol metabolite in elderly patients.
Plasma concentrations of pirprofen and of its pyrrol metabolite were assessed in 9 elderly patients (3 males, 6 females; mean age 76 years) suffering from chronic degenerative disease. Pirprofen 400 mg in 4 ml was administered i.m. and the pharmacokinetic profile of the drug and the metabolite was calculated. The AUC, Cmax and t1/2 of pirprofen were similar to those found in previous studies, and, as expected, those parameters for the pyrrol metabolite were lower (Cmax = 2.8 micrograms/ml-1; tmax = 6.4 h; AUC(0-32) = 56.5 micrograms.h.ml-1). One patient (n = 8) showed different pharmacokinetic behaviour, which is discussed. The data suggest that age has little influence on the pharmacokinetic of pirprofen, although unpredictable responses should always be considered in clinical practice.
Rossi
F A
FA
Center of Rheumatology, USSL 11, Genova, Italy.
Ferrero
M
M
Balladore
G E
GE
Zecca
L
L
Fraschini
F
F
Ferrario
P
P
Bichisao
E
E
Monza
G C
GC
Maresca
V
V
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D010666:Phenylpropionates / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D011758:Pyrroles / Q000378:metabolism / Q000493:pharmacokinetics*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; D011758:Pyrroles; C008924:pirprofen